To better define the clinical characteristics, treatment patterns, and survival outcomes of patients with mantle cell lymphoma (MCL), we conducted a multinational retrospective registry study for newly diagnosed patients with MCL.
Clinical and laboratory data were collected from newly diagnosed MCL patients between January 2008 and December 2017 from 16 hospitals in South Korea, two in Malaysia, and one in Taiwan.
A total of 191 patients with MCL were enrolled in this retrospective registry study. The median age was 66 years (range, 38–90), and majority of the patients had advanced stage disease (n = 150, 83.8%). The most frequently administered 1st line regimen was R-CHOP like regimen (n = 117, 61.3%), followed by cytarabine containing regimen (n = 41, 21.5%). There was a significant difference in the treatment pattern between young (age < 65, n = 90) versus elderly patients (age ≥ 65, n = 101). Higher proportion of elderly patients received R-CHOP like regimen as 1st line regimen compared with young patients (72.3% vs. 48.9%), while cytarabine containing regimen was more frequently administered in young patients (38.9% vs, 5.9%). The treatment response to 1st line regimens were available in 176 patients. The overall response rate (ORR) and the complete response (CR) rate among these patients were 94.9% (n = 167) and 52.3% (n = 92), respectively. A total of 106 patients were treated with 2nd line regimen. The most frequently administered 2nd line regimen was ibrutinib (n = 29, 27.4%) and cytarabine based regimen (n = 29, 27.4%), followed by BR (n = 12, 11.3%). The treatment response to 2nd line regimens were available in 89 patients, and the ORR and the CR rate among these patients were 74.2% (n = 66) and 38.2% (n = 34), respectively. Survival outcomes will be updated and presented at the ESMO Asia Congress 2022.
The current study offers an opportunity to better understand the treatment patterns of patients with MCL in the Asia-Pacific region. The most commonly used 1st line regimen was R-CHOP like regimen. Ibrutinib and cytarabine based regimen were the most frequently administered 2nd line regimens.
Clinical trial identification
Legal entity responsible for the study
The work was funded by a research grant from Janssen Pharmaceuticals Ltd.
All authors have declared no conflicts of interest.